Literature DB >> 29300685

Development of novel vaccine vectors: Chimpanzee adenoviral vectors.

Jingao Guo1, Moumita Mondal1,2, Dongming Zhou1.   

Abstract

Adenoviral vector has been employed as one of the most efficient means against infectious diseases and cancer. It can be genetically modified and armed with foreign antigens to elicit specific antibody responses and T cell responses in hosts as well as engineered to induce apoptosis in cancer cells. The chimpanzee adenovirus-based vector is one kind of novel vaccine carriers whose unique features and non-reactivity to pre-existing human adenovirus neutralizing antibodies makes it an outstanding candidate for vaccine research and development. Here, we review the different strategies for constructing chimpanzee adenoviral vectors and their applications in recent clinical trials and also discuss the oncolytic virotherapy and immunotherapy based on chimpanzee adenoviral vectors.

Entities:  

Keywords:  Adenovirus; cancer; infectious disease; vaccine; vector; viral vector

Mesh:

Substances:

Year:  2018        PMID: 29300685      PMCID: PMC6067905          DOI: 10.1080/21645515.2017.1419108

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  55 in total

1.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

2.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Authors:  J E Ledgerwood; P Costner; N Desai; L Holman; M E Enama; G Yamshchikov; S Mulangu; Z Hu; C A Andrews; R A Sheets; R A Koup; M Roederer; R Bailer; J R Mascola; M G Pau; N J Sullivan; J Goudsmit; G J Nabel; B S Graham
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

3.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system.

Authors:  Jinyong Luo; Zhong-Liang Deng; Xiaoji Luo; Ni Tang; Wen-Xin Song; Jin Chen; Katie A Sharff; Hue H Luu; Rex C Haydon; Kenneth W Kinzler; Bert Vogelstein; Tong-Chuan He
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Authors:  Daphne A Stanley; Anna N Honko; Clement Asiedu; John C Trefry; Annie W Lau-Kilby; Joshua C Johnson; Lisa Hensley; Virginia Ammendola; Adele Abbate; Fabiana Grazioli; Kathryn E Foulds; Cheng Cheng; Lingshu Wang; Mitzi M Donaldson; Stefano Colloca; Antonella Folgori; Mario Roederer; Gary J Nabel; John Mascola; Alfredo Nicosia; Riccardo Cortese; Richard A Koup; Nancy J Sullivan
Journal:  Nat Med       Date:  2014-09-07       Impact factor: 53.440

5.  Development of a targeted gene vector platform based on simian adenovirus serotype 24.

Authors:  Natalya Belousova; Galina Mikheeva; Chiyi Xiong; Suren Soghomonian; Daniel Young; Lucia Le Roux; Katherine Naff; Luc Bidaut; Wei Wei; Chun Li; Juri Gelovani; Victor Krasnykh
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

Review 6.  Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission.

Authors:  Drew L Lichtenstein; William S M Wold
Journal:  Cancer Gene Ther       Date:  2004-12       Impact factor: 5.987

Review 7.  Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.

Authors:  Stefania Capone; Anna Morena D'Alise; Virginia Ammendola; Stefano Colloca; Riccardo Cortese; Alfredo Nicosia; Antonella Folgori
Journal:  Expert Rev Vaccines       Date:  2013-04       Impact factor: 5.217

8.  Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Authors:  Stephen B Kennedy; Fatorma Bolay; Mark Kieh; Greg Grandits; Moses Badio; Ripley Ballou; Risa Eckes; Mark Feinberg; Dean Follmann; Birgit Grund; Swati Gupta; Lisa Hensley; Elizabeth Higgs; Krisztina Janosko; Melvin Johnson; Francis Kateh; James Logue; Jonathan Marchand; Thomas Monath; Martha Nason; Tolbert Nyenswah; François Roman; Eric Stavale; Julian Wolfson; James D Neaton; H Clifford Lane
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

9.  Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Authors:  Stefano Colloca; Eleanor Barnes; Antonella Folgori; Virginia Ammendola; Stefania Capone; Agostino Cirillo; Loredana Siani; Mariarosaria Naddeo; Fabiana Grazioli; Maria Luisa Esposito; Maria Ambrosio; Angela Sparacino; Marta Bartiromo; Annalisa Meola; Kira Smith; Ayako Kurioka; Geraldine A O'Hara; Katie J Ewer; Nicholas Anagnostou; Carly Bliss; Adrian V S Hill; Cinzia Traboni; Paul Klenerman; Riccardo Cortese; Alfredo Nicosia
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

10.  Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab.

Authors:  Man Xing; Xiang Wang; Yudan Chi; Dongming Zhou
Journal:  Oncotarget       Date:  2016-05-10
View more
  23 in total

1.  Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection.

Authors:  Xiang Wang; Ping Zhou; Mangteng Wu; Kaiyan Yang; Jingao Guo; Xuchen Wang; Jun Li; Zihao Fang; Guiqin Wang; Man Xing; Dongming Zhou
Journal:  NPJ Vaccines       Date:  2020-07-09       Impact factor: 7.344

Review 2.  Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.

Authors:  Queenie Fernandes; Varghese Philipose Inchakalody; Maysaloun Merhi; Sarra Mestiri; Nassiba Taib; Dina Moustafa Abo El-Ella; Takwa Bedhiafi; Afsheen Raza; Lobna Al-Zaidan; Mona O Mohsen; Mariam Ali Yousuf Al-Nesf; Ali Ait Hssain; Hadi Mohamad Yassine; Martin F Bachmann; Shahab Uddin; Said Dermime
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

Review 3.  Role of Adenoviruses in Cancer Therapy.

Authors:  Sintayehu Tsegaye Tseha
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

Review 4.  High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.

Authors:  Ana Ricobaraza; Manuela Gonzalez-Aparicio; Lucia Mora-Jimenez; Sara Lumbreras; Ruben Hernandez-Alcoceba
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

5.  Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection.

Authors:  Xiang Wang; Ping Zhou; Mangteng Wu; Kaiyan Yang; Jingao Guo; Xuchen Wang; Jun Li; Zihao Fang; Guiqin Wang; Man Xing; Dongming Zhou
Journal:  NPJ Vaccines       Date:  2020-07-09       Impact factor: 7.344

6.  Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.

Authors:  Fengqin Zhu; Yibo Wang; Zhen Xu; Haiyang Qu; Hairong Zhang; Lingling Niu; Honglu Xue; Dehuai Jing; Heng He
Journal:  Mol Med Rep       Date:  2018-12-11       Impact factor: 2.952

7.  Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys.

Authors:  Catherine Collignon; Vanesa Bol; Aurélie Chalon; Naveen Surendran; Sandra Morel; Robert A van den Berg; Stefania Capone; Viviane Bechtold; Stéphane T Temmerman
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

8.  The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV.

Authors:  Senthil K Chinnakannan; Tamsin N Cargill; Timothy A Donnison; M Azim Ansari; Sarah Sebastian; Lian Ni Lee; Claire Hutchings; Paul Klenerman; Mala K Maini; Tom Evans; Eleanor Barnes
Journal:  Vaccines (Basel)       Date:  2020-04-14

Review 9.  COVID-19 vaccines: The status and perspectives in delivery points of view.

Authors:  Jee Young Chung; Melissa N Thone; Young Jik Kwon
Journal:  Adv Drug Deliv Rev       Date:  2020-12-24       Impact factor: 17.873

Review 10.  Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.

Authors:  Vivek P Chavda; Lalitkumar K Vora; Anjali K Pandya; Vandana B Patravale
Journal:  Drug Discov Today       Date:  2021-07-29       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.